Kalaris Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by AKKARAJU SRINIVAS, was filed 22 May 2026.
Kalaris Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Kalaris Therapeutics, Inc. as filed with SEC (Form 4), a company from the Health Care sector. In the past year (23 October 2025 to 23 October 2026), 7 filings came from 2 insiders.
On the market, 1 insider bought (2 purchases totalling €5.3M) while 1 insider sold (1 sale totalling €11k). Netting one side against the other leaves €5.3M of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a purchase of €4.3M by Akkaraju Srinivas, published on 17 February 2026. The buyers include 1 senior executive.
Compared with its exchange (3,167 companies, median 24 filings), a count of 7 filings is below the norm. Since 2020, the database holds 10 purchases and 343 sales by insiders of the company.
The last insider purchase was made public on 22 May 2026, 170 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -61.2%Entry US$5.21 · Close 21 Oct 2026 US$2.02
- -79.0%Entry US$79.12 · Close at T+365 US$16.63
- -18.2%Entry US$104.65 · Close at T+365 US$85.56
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Kalaris Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$18.71.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 244,300 shares@ US$4.835.6% of flowCommon StockSEC:0001231919-26-000532:0Canonical exit: 18 Aug 2026 (T+90)
- 66,906 shares0Common StockSEC:0001231919-26-000532:1
- 14,937 shares0Common StockSEC:0001231919-26-000532:2
- 4,471 shares0Common StockSEC:0001231919-26-000532:3
- 1,915 shares@ US$6.7259.6% of flowCommon StockSEC:0001193125-26-119707:0
- 479,847 shares@ US$10.4223.5% of flowCommon StockSEC:0001231919-26-000166:0Canonical exit: 18 Mar 2026 (T+90)
- 1,500,000 shares@ US$10.0070.8% of flowCommon StockSEC:0001231919-25-000652:0
- 907 shares@ US$8.969340.4% of flowCommon StockSEC:0000950170-25-046263:0
- 100,800 sharesCommon StockSEC:0000950170-25-041496:1
- 11,444,503 sharesCommon StockSEC:0000950170-25-041484:0
- 504,000 sharesCommon StockSEC:0000950170-25-041498:0
- 4,030 sharesCommon StockSEC:0000950170-25-041494:0
- 252,000 sharesCommon StockSEC:0000950170-25-041496:0
- 106 shares@ US$10.07582.1% of flowCommon StockSEC:0000950170-25-025630:0
- 303 shares@ US$10.07580.0% of flowCommon StockSEC:0000950170-25-025634:0
- 96 shares@ US$10.07580.6% of flowCommon StockSEC:0000950170-25-025633:0
- 5 shares@ US$9.940.0% of flowCommon StockSEC:0000950170-25-009205:1
- 4 shares@ US$9.940.0% of flowCommon StockSEC:0000950170-25-009204:1
- 13 shares@ US$9.940.0% of flowCommon StockSEC:0000950170-25-009197:1
- 116 shares@ US$9.45380.0% of flowCommon StockSEC:0000950170-25-009197:0
- 47 shares@ US$9.45380.9% of flowCommon StockSEC:0000950170-25-009205:0
- 32 shares@ US$9.45380.2% of flowCommon StockSEC:0000950170-25-009204:0
- 332 shares@ US$0.44010.1% of flowCommon StockSEC:0000950170-25-004833:0
- 409 shares@ US$0.44010.4% of flowCommon StockSEC:0000950170-25-004834:0
- 979 shares@ US$0.44010.0% of flowCommon StockSEC:0000950170-25-004832:0
25 of 452 declarations
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It is listed on NASDAQ under the ticker XNAS.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
